Filed Pursuant to Rule 424(b)(7)
Registration No. 333-204911
PROSPECTUS SUPPLEMENT
(To Prospectus Dated June 12, 2015)

178,724 Shares of Common Stock
The following information supplements and amends the prospectus dated June 12, 2015 (the “Prospectus”), and the prospectus supplement dated March 2, 2018 (the “March Prospectus Supplement”) relating to the possible resale, from time to time, by the selling stockholders named in this prospectus supplement of an additional 15,466 shares of our common stock, $0.01 par value per share. This supplement should be read in conjunction with, and is qualified by reference to, the Prospectus and the March Prospectus Supplement, except to the extent that the information in this prospectus supplement supersedes the information contained in the Prospectus and the March Prospectus Supplement.
On March 2, 2018, pursuant to the March Prospectus Supplement we registered 258,061 shares of our common stock, $0.01 par value per share, for the benefit of certain selling stockholders. In August 2018, we disbursed additional shares of our common stock, $0.01 par value per share, from escrow to the selling stockholders listed below (the “Escrow Release”). To update the information contained in the section of the March Prospectus Supplement entitled “Selling Stockholders” to reflect the Escrow Release, the selling stockholder table has been revised to include the additional shares issued to certain selling stockholders following the Escrow Release.
Investing in the Registered Shares involves risk. Before buying any Registered Shares you should carefully read the discussion of material risks of investing in the Registered Shares referred to in “Risk Factors” beginning on pageS-4 of the March Prospectus Supplement and page 3 of the Prospectus, including those risks set forth beginning on page 8 of our Annual Report on Form10-K for the year ended December 31, 2017, and in the documents we incorporate by reference.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.